Atelerix Life Sciences
Indianapolis, US · Founded 2020 · Delaware corporation · 1 known investors
Find your way into Atelerix Life Sciences
Sign up to see every warm intro you have to Atelerix Life Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Atelerix Life Sciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Atelerix Life Sciences develops novel respiratory therapies for drug-induced respiratory depression, respiratory disease exacerbations, and bio-defense against respiratory threats. The company is advancing pre-clinical and clinical-stage drug candidates, with ATLX-0199 as its lead compound designed to stimulate respiratory drive while preserving pain relief and sedation.
Founders & leadership

Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$650K disclosed across 1 round · 2022
▶$650KraisedOct 2022 · 2 investors · BiotechnologyRule 506(b)
- David KalergisExecutive Officer, Director, Promoter
- William AkridgeDirector
- Peter Barton HuttDirector
- Offering amount
- $3.5M
- Amount sold
- $650K
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Atelerix Life Sciences.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.8M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Atelerix Life Sciences do?
- Atelerix Life Sciences develops novel respiratory therapies for drug-induced respiratory depression, respiratory disease exacerbations, and bio-defense against respiratory threats. The company is advancing pre-clinical and clinical-stage drug candidates, with ATLX-0199 as its lead compound designed to stimulate respiratory drive while preserving pain relief and sedation.
- Who are Atelerix Life Sciences's investors?
- Atelerix Life Sciences's investors include CWRU Technology Ventures.
- How much funding has Atelerix Life Sciences raised?
- Atelerix Life Sciences has disclosed $650K raised across 1 round.
- Where is Atelerix Life Sciences headquartered?
- Atelerix Life Sciences is headquartered in Indianapolis, US.

